Full metadata record
DC FieldValueLanguage
dc.creatorAlegre, A. (A.)-
dc.creatorRubia, J. (Javier) de la-
dc.creatorSureda-Balari, A. (Anna)-
dc.creatorEncinas-Rodríguez, C. (Cristina)-
dc.creatorSuárez, A. (Alexia)-
dc.creatorBlanchard, M.J. (María Jesús)-
dc.creatorBargay-Lleonart, J. (Joan)-
dc.creatorRodriguez-Otero, P. (Paula)-
dc.creatorInsunza, A. (Andrés)-
dc.creatorPalomera, L. (Luis)-
dc.creatorPeñarrubia, M.J. (María Jesús)-
dc.creatorRíos-Tamayo, R. (Rafael)-
dc.creatorCasado-Montero, L.F. (Luis Felipe)-
dc.creatorGonzález, M.S. (Marta Sonia)-
dc.creatorPotamianou, A. (Anna)-
dc.creatorCouturier, C. (Catherine)-
dc.creatorPei, H. (Huiling)-
dc.creatorHevia, H. (Henar)-
dc.creatorMilionis, I. (Iordanis)-
dc.creatorGaudig, M. (Maren)-
dc.creatorMateos, M.V. (María Victoria)-
dc.identifier.citationAlegre, A. (A.); Rubia, J. (Javier) de la; Sureda-Balari, A. (Anna); et al. "Results of an early access treatment protocol of daratumumab monotherapy in spanish patients with relapsed or refractory multiple myeloma". Hemasphere. 4 (3), 2020, e380es_ES
dc.description.abstractDaratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided early access to daratumumab monotherapy and collected safety and patient-reported outcomes data for patients with relapsed or refractory multiple myeloma. At 15 centers across Spain, intravenous daratumumab (16mg/kg) was administered to 73 patients who had ≥3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or who were double refractory to both. The median duration of daratumumab treatment was 3.3 (range: 0.03–13.17) months, with a median number of 12 (range: 1–25) infusions. Grade 3/4 treatment-emergent adverse events were reported in 74% of patients and included lymphopenia (28.8%), thrombocytopenia (27.4%), neutropenia (21.9%), leukopenia (19.2%), and anemia (15.1%). Common (>5%) serious treatmentemergent adverse events included respiratory tract infection (9.6%), general physical health deterioration (6.8%), and back pain (5.5%). Infusion-related reactions occurred in 45% of patients. The median change from baseline in all domains of the EQ-5D-5L and EORTC QLQ-C30 was mostly 0. A total of 18 (24.7%) patients achieved a partial response or better, with 10 (13.7%) patients achieving a very good partial response or better. Median progression-free survival was 3.98 months. The results of this early access treatment protocol are consistent with previously reported trials of daratumumab monotherapy and confirm its safety and antitumoral efficacy in Spanish patients with heavily treated relapsed or refractory multiple myeloma.es_ES
dc.description.sponsorshipThis study was funded by Janssen Research & Development, LLC. Editorial and medical writing support were provided by J. Matthew Kuczmarski, PhD, of MedErgy, and were funded by Janssen Global Services, LLC. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.es_ES
dc.publisherWolters Kluwer Healthes_ES
dc.subjectAntibody approvedes_ES
dc.subjectMultiple myelomaes_ES
dc.titleResults of an early access treatment protocol of daratumumab monotherapy in spanish patients with relapsed or refractory multiple myelomaes_ES
dc.description.noteThis is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.es_ES

Files in This Item:
527.85 kB
Adobe PDF

Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.